Literature DB >> 1491839

Cognition and 99Tcm-HMPAO SPECT in Parkinson's disease.

R S Liu1, K N Lin, S J Wang, D E Shan, J L Fuh, S H Yeh, H C Liu.   

Abstract

99Tcm-hexamethylpropyleneamine oxime (HMPAO) single photon emission computed tomography (SPECT) of brain was performed in 43 unselected patients with Parkinson's disease to evaluate whether low cerebral perfusion on SPECT correlated with cognitive impairment in the patients. All patients received neurological, Mini-Mental State Examination and a neuropsychological assessment. Eighteen (41.9%) of the 43 patients were demented. Thirty patients (69.8%) had abnormal SPECT: 17 had perfusion defects in cortical regions, eight in basal ganglia and five in both regions. Of the 22 patients with abnormal cortical perfusion, 15 (68.2%) were demented; only three (14.3%) of the 21 patients without cortical defect were demented (P < 0.01). Twelve of the 15 demented patients had low perfusion in the parietal region alone or in parietal and occipital regions. The cortical perfusion defects, present in 22 (51.2%) Parkinson's patients, are highly correlated with cognitive impairment. The pattern of SPECT abnormality in most demented patients with Parkinson's disease is similar to that seen in Alzheimer's disease, suggesting that the underlying pathophysiology for dementia in patients with Parkinson's disease may be similar to that in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1491839

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  3 in total

1.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

2.  Regional CBF changes in Parkinson's disease: the importance of functional neuroimaging analyses.

Authors:  Bárbara J Amorim; Erica C S Camargo; Elba C S C Etchebehere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09       Impact factor: 9.236

3.  SPECT neuroimaging and neuropsychological functions in different stages of Parkinson's disease.

Authors:  Anna Paschali; Lambros Messinis; Odysseas Kargiotis; Velissarios Lakiotis; Zinovia Kefalopoulou; Costantinos Constantoyannis; Panagiotis Papathanasopoulos; Pavlos Vassilakos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-10       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.